Aim: To examine the cell membrane transporters involved in mediating the antilipolytic effect of biguanides in human fat cells.
mediated lipolysis activation. At least in human fat cells, the most important action seems to be stimulation of AMP-activated protein kinase (AMPK), which counteracts the pro-lipolytic effect of cyclic AMP. 10 Given the marked polarity of metformin, an important aspect in mediating its action is the cellular uptake via membrane transporters. 12 A large number of such transporters have been identified, including organic cation transporters-1, −2, and −3 (OCT1-3, encoded by SLC22A1, SLC22A2 and SLC22A3, respectively), organic cation transporter novel type 1/ergothioneine transporter (OCTN1/ETT, encoded by SLC22A4), multidrug and toxin extrusion transporters-1 and -2 (MATE1 and MATE2, encoded by SLC47A1 and SLC47A2, respectively) as well as plasma membrane monoamine transporter (PMAT, encoded by SLC29A4). 13 While the role of these transporters for the antilipolytic effect of metformin is unknown, some OCTs have been investigated in human fat cells with regard to lipogenesis and AMPK activity. 14 This showed that OCT1, but not OCT2, was expressed in adipocytes and that cimetidine (a non-specific inhibitor of OCTs and MATEs) counteracted the effects of metformin.
The antilipolytic actions of metformin are observed in vivo at therapeutic doses, 5, 6 but the in vitro effects are only observed using high millimolar concentrations of the drug. It could be argued that, at these levels, the effect of metformin is purely pharmacological.
Recently, more potent biguanide analogues have been developed for the treatment of metabolic disorders and cancer. Thus, NT1014 and NT1044 ( Figure 1A ) have been evaluated in models for ovarian cancer and endometrial cancer. 15 These studies showed that both compounds suppressed cancer cell growth through their effects on the AMPK/ mTor pathways, resulting in G1 cell cycle arrest and apoptosis.
In the present study, we compared the antilipolytic effects of metformin in human adipocytes with those of NT1014 and NT1044, and found that the two novel biguanides display significantly more potent antilipolytic effects compared with metformin. To better understand whether these differences could be explained by cellular uptake, we mapped all known biguanide transporters in human subcutaneous fat cells. Furthermore, we downregulated the adipocyte-expressed transporters by RNA interference (RNAi) and compared the changes in the antilipolytic effects of metformin, NT1014 and NT1044.
2 | METHODS
| Participants
Freshly isolated adipocytes were obtained from 14 participants. Their clinical characteristics are shown in Table 1 . Five participants were diagnosed with type 2 diabetes, all were treated with lifestyle interventions and none were on insulin or glitazone treatment.
All remaining participants were healthy. Participants were consecutively recruited at our outpatient clinic and were not selected based on body mass index, age or gender. Exclusion criteria were ongoing (B) (A) (D) (C) FIGURE 1 Effects of biguanides in human fat cells. A, Structure of NT1014 and NT1044, respectively. B, Concentration-dependent antilipolytic effects of indicated biguanides in in vitro differentiated adipocytes from Zenbio, expressed as release of non-esterified fatty acids (NEFA). Data based on three independent experiments. C, Concentration-dependent effects on AMP-activated protein kinase (AMPK) activation in in vitro differentiated adipocytes from Zenbio. Data based on three independent experiments. Results were first analysed by analysis of variance (ANOVA) to confirm differences between treatments; asterisks denote significant differences in post hoc tests (paired t test) compared with control cells. D, Antilipolytic effects of biguanides in mature fat cells isolated from 14 individuals. Overall P value using ANOVA is shown, b indicates statistically different from control (P < .05) and c indicates statistically different from metformin incubated cells (P < .05) in post hoc tests (paired t test). *P < .05, **P < .01, ***P < .001 treatment with metformin, glitazones and/or insulin, and uncontrolled hypertension. After clinical examination, adipocytes were isolated from subcutaneous abdominal fat biopsies as described below. All samples were handled by the same research nurse and technician. The study was approved by the regional ethics board and informed written consent was obtained from all participants.
| Adipocyte isolation from adipose tissue
Adipose tissue was rinsed repeatedly in saline, and visual blood vessels and cell debris were removed. Tissue specimens (~1 g) were divided into portions, one of which was subjected to collagenase treatment to obtain isolated adipocytes as described. 16 The remaining part of the adipose samples (~300 mg) was immediately frozen in liquid nitrogen for subsequent RNA isolation as described below.
| Lipolysis in mature adipocytes isolated from tissue biopsies
Diluted adipocyte suspensions (2% vol/vol) were incubated in duplicates for 2 hours with air as the gas phase at 37 C in Krebs-Ringer phosphate buffer (pH 7.4) supplemented with glucose (8.6 mmol/L), ascorbic acid (0.1 mg/mL) and bovine serum albumin (BSA; 20 mg/mL). Cells were treated with 5 nmol/L of isoprenaline in the absence or presence of increasing concentrations of met- for the OCR effect) for up to 24 hours had effects on cell proliferation. For metformin, even these high concentrations had small effects on cell proliferation (15%-30% reduction).
| Gene knockdown experiments and viability assays
Studies were performed in hASCs cultured as described above. Cells (a measure of cell membrane integrity) was also performed in the conditioned media using cytotoxicity detection kit (Roche, Basel, Switzerland).
This showed no significant effect of our treatments (data not shown).
| Quantitative RT-PCR and gene expression analyses
White adipose tissue (WAT) specimens from the clinical samples were disrupted mechanically and RNA isolated using the RNeasy kit 22 For expression studies of biguanide transporters in human preadipocytes and adipocytes (Zenbio Inc.), total RNA was isolated and cDNA was generated using 2 μg of RNA (ABI High Capacity cDNA reverse transcription kit #4368814, Waltham, Massachusetts).
Quantitative PCR for each cDNA was conducted with Taqman probes using iTaq Universal Probe Supermix (BioRad, Hercules, California).
Microarray data of different resident cells in human subcutaneous adipose tissue were generated as described. 23 
| Analysis of protein expression
The hASCs were transfected with siRNA as described above and plated in 6-well plates at a density of 500 000 cells. On day 12 of differentiation, cells were lysed in RIPA buffer as described. 24 were used (Sigma-Aldrich). Proteins were detected by chemiluminescence using the ECL Select Western Blotting Detection Kit (GE Healthcare) in the Chemidoc XRS system (Bio-Rad, Hercules, California) and quantified using Quantity One software (Bio-Rad). between the degree of metformin-induced inhibition of lipolysis and circulating NEFA levels (graph not shown). This suggests that participants with elevated S-NEFA concentrations may exhibit a more pronounced effect of metformin. In contrast, the antilipolytic effects of NT1014 and NT1044 showed no relationship with NEFA levels (graphs not shown). Five of the participants were diagnosed with type 2 diabetes, but the effects of the 3 biguanides were similar in participants with or without diabetes (graphs not shown).
| Glucose tolerance tests in animals

| Affinity of biguanides to cellular transporters
The relative affinity of specific biguanide transporters for cellular uptake was compared in HEK293 cells overexpressing individual transporters (Table 2 ). These cells express negligible endogenous levels of each transporter. Effects were determined by assessing the inhibitory effects of metformin, NT1014 and NT1044 on OCR, providing a "functional" measure of biguanide affinity for each transporter, and were expressed as IC 50 . All three biguanides reduced OCR in a concentration-responsive manner (graphs not shown). Under these experimental conditions, the "affinity" for metformin and both biguanide analogues was highest for OCT1-3 and PMAT, and lowest for OCTN1 and MATE1. The potency of NT1014 and NT1044 vs metformin was again underscored by the~10 times lower IC 50 values observed for all transporters (except OCTN1 for NT1044). Importantly, the IC 50 values observed in this artificial cell system cannot be extrapolated to treatments in cells expressing endogenous transporter levels.
| In vivo effects of biguanides
The efficacy of the novel biguanides was tested in an animal model. 
| Gene and protein expression of biguanide transporters in human adipocytes
To identify transporters of importance for mediating the antilipolytic effects in human adipocytes, the gene expression of all seven hitherto described biguanide transporters was determined by qPCR in hASCs Figure S3A-D) . This showed that OCT3, PMAT and MATE1 were clearly detectable ( Figure S3A-C) . Despite the low expression of SLC22A1, based on the data described above, 14 we chose to analyse OCT1 protein as well and compared that to the levels in liver, an organ that is well established to express OCT1. Using one commercially available antibody, a band corresponding to the size of OCT1 (61 kD) was observed in liver while a stronger band with a slightly larger size was observed in differentiated and nondifferentiated adipocytes in both membrane and cytosol fractions ( Figure S3D ). We therefore opted to test a second OCT1-directed antibody. This showed that while there was a clear band in liver, there was no corresponding band in in vitro differentiated adipocytes ( Figure S3D ). Taken together, this suggests that OCT1 protein is not expressed to any significant degree in human adipocytes and further studies were therefore not pursued on this transporter.
| Downregulation of biguanide transporters in human adipocytes
The role in mediating the antilipolytic effects of biguanides was tested by knocking down the corresponding transporter genes by siRNA in human adipocytes, followed by incubations with isoprenaline with or without metformin, NT1014 or NT1044 (Figure 4 ). RNAi efficiently reduced the levels of SLC22A3, SLC29A4 and SLC47A1 by >85% ( Figure S3E ). This was reflected by significantly attenuated levels of MATE1 and PMAT protein (>65%), although knockdown of OCT3 was less pronounced (~30%; Figure S3A -C,E). Downregulation of SLC22A3 (OCT3) did not affect the antilipolytic effects of any of the biguanides ( Figure 4A ; biguanide concentrations same as in Figure 1D ). In contrast, siRNAs against Figure S4 ). Altogether, this suggests that PMAT mediates uptake of all three biguanides, while MATE1 is relevant for metformin uptake, at least at the supra-pharmacological concentrations used in the present study.
| DISCUSSION
Several cationic transporters mediating metformin uptake have been described in recent years 13 ; however, their inter-individual importance, particularly in adipose tissue, is still unclear. Given that the antilipolytic effects of biguanides may contribute to their antidiabetic actions, we mapped cell membrane transporters of functional relevance in human adipocytes. Our data show that five genes are detectable in WAT, three of which are expressed at physiologically relevant levels and upregulated during adipocyte differentiation.
Among the latter, two (OCT3 and PMAT) are specific for adipocytes, while MATE1 is enriched in the same cell fraction. A caveat when assessing the effects of metformin in experimental models is that suprapharmacological doses are often used. In the present study, we therefore assessed the effects of NT1014 and NT1044, two biguanide analogues displaying significantly higher affinity to all cell membrane transporters as well as higher potency and efficacy on fat cell AMPK activation and antilipolysis compared with metformin. We performed a set of functional assays to determine the transporters primarily mediating biguanide uptake in human adipocytes. As selective inhibitors of cationic transporters are not available, we studied the effects of the biguanides after gene knockdown by siRNA. Our findings confirm that the compounds display differential sensitivity to specific transporters and that PMAT appears to be of particular relevance in mediating uptake and thereby the antilipolytic effects of both metformin and novel biguanides in human adipocytes.
Despite more than six decades of clinical use, the exact mechanism of action of biguanides remains elusive. Although it has been contested by some groups, 25 AMPK activation is still suggested by many independent investigators to mediate most of the effects induced by metformin, including antilipolysis. 10 In line with this notion we could confirm that metformin as well as NT1014 and Finally, while it was outside the scope of the present study, it would be of interest to compare the effects of metformin, NT1014
and NT1044 in different cell types in vitro as well as in different tissues in vivo. According to the Human Protein Atlas, the liver/ gallbladder primarily expresses OCT1, OCTN1, OCT3 and MATE1
while muscle primarily expresses OCT1, OCT3 and MATE1. It should be noted that neither tissue expresses PMAT to any significant extent; in fact, PMAT appears to be quite specific to adipose tissue.
In summary, the present study suggests that the antilipolytic effects of two novel biguanides can be obtained with pharmacologically relevant concentrations and that development of potent analogues with high affinity to the cationic transporter PMAT could be useful as novel antidiabetic agents targeting lipolysis in adipocytes.
Comparisons of biguanides with different transporter affinities could help decipher the tissue-specific relevance of biguanide-induced effects in vivo.
